BUZZ-Ironwood rises after US sets Medicare price for constipation drug
Shares of drugmaker Ironwood Pharmaceuticals’shares rise 1.3% to $3.17 premarketCo says U.S. Department of Health and Human Services has set the new Medicare price for co’s Linzess at $136 for a 30-day supplyCo’s Linzess treats chronic constipation and irritable bowel syndrome with constipation - IRWDNew price will apply from Jan. 1, 2027 under Inflation Reduction Act, co saysCo says revised price aligns with its expectationsUp to last close, stock down ~30% YTD
Shares of drugmaker Ironwood Pharmaceuticals’ (IRWD.O) shares rise 1.3% to $3.17 premarket
Co says U.S. Department of Health and Human Services has set the new Medicare price for co’s Linzess at $136 for a 30-day supply
Co’s Linzess treats chronic constipation and irritable bowel syndrome with constipation - IRWD
New price will apply from Jan. 1, 2027 under Inflation Reduction Act, co says
Co says revised price aligns with its expectations
Up to last close, stock down ~30% YTD
